by Kevin Robb | Jun 29, 2023
Mesenchymal stromal cells (MSCs) have been at the front line of cell therapy and regenerative medicine efforts for decades. Investigators hotly pursued MSCs as prospective cell therapies for a wide range of diseases, but enthusiasts were left wanting when several...
by Sara M. Nolte | Jun 21, 2023
In addition to showers, flowers and warmer weather, this spring also brought renewed hope for patients with hematological malignancies undergoing stem cell transplants (SCTs) in the form of the approval of Gamida Cell’s Omisirge® (omidubicel). This cell-based therapy...
by Stacey Johnson | Jun 2, 2023
The Networks of Centres of Excellence (NCE) program has been on my mind lately. Yes it’s true, although it may seem odd to admit. The Government of Canada’s innovative program, launched in 1989, was intended to “mobilize Canada’s best research, development and...
by Don Gibbons | May 25, 2023
A recent Wall Street Journal article reminded me of the work of someone I came to know well while at the California Institute for Regenerative Medicine (CIRM): Jeanne Loring of the Scripps Research Institute. The article detailed a cell therapy for Parkinson’s Disease...
by Cal Strode | May 18, 2023
Regular readers of Alliance for Regenerative Medicine (ARM) sector reports may have noticed that the organization is taking a new approach to sharing insights on the cell and gene therapy sector. In April, ARM launched a new format for distilling key data and trend...
by Cal Strode | Apr 27, 2023
The first Science Huddle panel discussion of 2023, Cell & Gene Therapy: Maximizing Commercialization, delved into challenges keeping leaders in the cell and gene therapy (CGT) commercialization space up at night. Moderating the event was Dr. Christian K....
Comments